Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study - Martin, Allison; Smith, Don E; Carr, Andrew; Ringland, Clare; Amin, Janaki; Emery, Sean; Hoy, Jennifer; Workman, Cassy; Doong, Nicholas; Freund, Judith; Cooper, David A (AIDS (London), 2004)
Keywords: Absorptiometry, Photon; Adipose Tissue - pathology; Anti-HIV Agents - adverse effects; Anti-HIV Agents - therapeutic use; Biological and medical sciences; Body Composition - drug effects; Bone Density - drug effects; Dermatology; Dideoxynucleosides - therapeutic use; Follow-Up Studies; HIV Infections - drug therapy; HIV-Associated Lipodystrophy Syndrome - chemically induced; HIV-Associated Lipodystrophy Syndrome - pathology; Human viral diseases; Humans; Infectious diseases; Medical sciences; Reverse Transcriptase Inhibitors - adverse effects; Reverse Transcriptase Inhibitors - therapeutic use; Skin involvement in other diseases. Miscellaneous. General aspects; Stavudine - adverse effects; Stavudine - therapeutic use; Viral diseases; Viral diseases of the lymphoid tissue and the blood. Aids; Zidovudine - adverse effects; Zidovudine - therapeutic use; Australia; Oceania; Skin disease; Purine nucleoside; RNA-directed DNA polymerase; Prognosis; Check; Thymidine; Stavudine; Fat mass; thymidine analogues; Prevention; Design; Reverse transcriptase inhibitor; Limb; Antiviral; Ambulatory; Pyrimidine nucleoside; HIV lipodystrophy; Human; Immunopathology; Enzyme; Critically ill; Subcutaneous; Transferases; Enzyme inhibitor; Retroviridae; Definition; AIDS; Immune deficiency; Lentivirus; Long term; Infection; Virus; Nucleotidyltransferases; Chemotherapy; Lipoatrophy; Dideoxynucleoside; Viral disease; Abacavir; Lipodystrophy; Reversibility; Nucleosidic analog; Adipose tissue disorders; Human immunodeficiency virus; Arm; Zidovudine